 2027年～2037年の世界のポリソルベート市場The Global Polysorbate Market 2027-2037 ポリソルベートは、ソルビトール、エチレンオキシド、および脂肪酸を原料とする非イオン性界面活性剤の一群であり、PS20、PS40、PS60、PS80という4つの主要な種類が商業的に製造されている。これらはそれぞ... もっと見る
サマリー ポリソルベートは、ソルビトール、エチレンオキシド、および脂肪酸を原料とする非イオン性界面活性剤の一群であり、PS20、PS40、PS60、PS80という4つの主要な種類が商業的に製造されている。これらはそれぞれ、主成分となる脂肪酸エステルと、それに対応する配合特性によって区別される。 乳化剤や安定剤として一見単純に見えるにもかかわらず、市販のポリソルベートは化学的に複雑な物質である。 PS20だけでも、エステル化部位とポリオキシエチレン鎖の長さの確率的分布に起因して、27,000種以上の個別の分子種から構成されており、この不均一性は、ロット間の一貫性、分析的特性評価、および規制順守に重大な影響を及ぼします。 世界のポリソルベート市場は、幅広い最終用途産業に及んでいます。医薬品およびバイオ医薬品は最も高価値なセグメントを占めており、特にポリソルベート80は、注射用バイオ医薬品においてほぼ普遍的に採用される界面活性剤として機能しています。 モノクローナル抗体、バイオシミラー、ワクチン、脂質ナノ粒子ベースのmRNA治療薬、およびパクリタキセルやドセタキセルなどの抗がん剤注射剤など。 これらの製剤におけるポリソルベートの機能は極めて重要である。通常0.01%～0.1%（w/v）の濃度で、界面でのタンパク質の凝集を防ぎ、充填・仕上げ工程中の機械的ストレスから保護し、保存期間を通じて製品の安定性を維持する。 医薬品以外にも、ポリソルベートは食品用乳化剤（EUではE432～E436と指定）、化粧品やパーソナルケア製品における可溶化剤やテクスチャー剤、さらには農薬や工業用洗浄剤の分散剤として広く使用されています。 市場は、3つの明確な品質レベルで構成されています。複数の薬典規格に準拠したグレードのポリソルベートは、USP/NF、欧州薬局方、および日本薬局方の要件を同時に満たしており、市場の主要な販売量を占めていますが、その供給は中国およびインドのメーカーが支配しています。 「超精製グレード」は、過酸化物価の大幅な低減、より厳しいエンドトキシン基準、および管理された脂肪酸プロファイルが特徴であり、大幅な価格プレミアムが付いており、非経口投与、眼科用、およびワクチン用途での指定が増加しています。 その頂点に位置するのが「超純度グレード」であり、世界中で6社未満の認定メーカーによって生産されている。これは、過酸化物レベルがサブppbレベルであり、エンドトキシンが極めて低いことが必須条件となる、最も要求の厳しいバイオ医薬品用途を対象としている。 2037年までの成長は、主にバイオ医薬品およびバイオシミラーのパイプライン、LNP（リポナノ粒子）ベースの核酸治療薬の急速な拡大、そして製剤開発者が複数の薬典規格に準拠したグレードから高純度グレードへと移行するにつれて広がるプレミアム化の傾向によって牽引される。 一方で、原料価格の変動、ポリソルベートの分解生成物（特にバイオリアクターで製造されるバイオ医薬品における宿主細胞リパーゼによる加水分解）に対する規制当局の監視強化、および非非経口用途におけるポリグリセリルエステルやポロキサマーへの代替関心の高まりなどが、逆風要因として挙げられます。 超高純度グレードにおけるサプライチェーンの集中は構造的なリスクを呈しており、バイオ医薬品の調達チームは、デュアルソースの認定や長期契約の締結を通じて、この問題への対応を強化している。 『2027年～2037年の世界のポリソルベート市場』は、2037年までの10年間にわたり、世界のポリソルベート市場で事業を展開している、あるいは同市場を評価している組織にとって、決定的な商業情報リソースを提供します。 主要ステークホルダーへのインタビュー、貿易データの分析、薬局方および規制文書のレビュー、独自のボトムアップ型市場モデリングを組み合わせて作成されており、製品タイプ、品質グレード、原産地、物理的形態、最終用途セクター、および地域ごとに細分化された詳細な売上高および販売量の予測を提供します。 すべての予測は、2025年および2037年の両時点での数値とともに提示され、完全なCAGR（年平均成長率）分析も併せて掲載されています。 本レポートは、ポリソルベートメーカー、製薬企業の製剤開発担当者および調達チーム、特殊化学品販売業者、バイオ医薬品CDMO、薬事部門、ならびに特殊賦形剤分野を評価する金融アナリストや投資家など、幅広い専門家の読者を対象として構成されています。その最大の特徴は、3段階のグレード体系です。 「マルチコンペンディアル」、「スーパーリファインド」、「ウルトラピュア」です。このフレームワークは、市場規模の推計、競合ポジショニング、価格分析、規制に関する解説、および全19社の企業プロファイルに一貫して適用されており、これらのグレードが根本的に異なる顧客層に提供され、価格帯も大きく異なり、供給元となるメーカーもますます多様化しているという、商業的に極めて重要な現実を反映しています。 バイオ医薬品用ポリソルベート市場に関する専用章—— 本レポートで最も充実したセクションであるこの章では、ウルトラピュアおよびスーパーリファインドの需要拡大を牽引する注射剤の全領域、すなわちモノクローナル抗体、バイオシミラー、mRNA脂質ナノ粒子プラットフォーム、遺伝子治療ベクター、抗がん剤注射剤、および眼科用バイオ医薬品について取り上げています。 この章では、ポリソルベートの分解リスク管理、ICH Q8およびQ9に基づく規制上の適格性要件、サプライヤーごとのDMFおよびCEPの申請状況、そして認定メーカーが6社未満しか世界市場に供給していない「超純度」グレードにおける供給安定性の評価について、詳細に論じています。 地域別分析では7つの地域を網羅し、最も価値の高い市場については国レベルでの詳細な分析を行っています。競争環境に関する章では、18社の製造業者をアルファベット順に紹介し、各社についてグレードの幅、製造拠点、規制認証、戦略的方向性、および体系的なSWOT分析に基づいて評価しています。 レポートの内容は以下の通りです：
Summary
Polysorbates are a family of non-ionic surfactants derived from sorbitol, ethylene oxide, and fatty acids, produced commercially in four principal variants — PS20, PS40, PS60, and PS80 — each distinguished by its dominant fatty acid ester and corresponding formulation properties. Despite their apparent simplicity as emulsifiers and stabilisers, commercial polysorbates are chemically complex materials: PS20 alone comprises more than 27,000 individual molecular species arising from the stochastic distribution of esterification sites and polyoxyethylene chain lengths, a heterogeneity that has profound implications for batch consistency, analytical characterisation, and regulatory compliance.
The global polysorbate market spans a wide range of end-use industries. Pharmaceuticals and biopharmaceuticals represent the highest-value segment, with polysorbate 80 in particular serving as the near-universal surfactant of choice in injectable biologics — including monoclonal antibodies, biosimilars, vaccines, lipid nanoparticle-based mRNA therapeutics, and oncology injectables such as paclitaxel and docetaxel. Its function in these formulations is critical: at concentrations typically between 0.01% and 0.1% w/v, it prevents protein aggregation at interfaces, protects against mechanical stress during fill-finish operations, and maintains product stability throughout shelf life. Beyond pharmaceuticals, polysorbates are extensively used as food emulsifiers (designated E432–E436 in the EU), as solubilisers and texture agents in cosmetics and personal care products, and as dispersants in agrochemical and industrial cleaning formulations.
The market is structured around three distinct quality tiers. Multicompendial-grade polysorbate meets simultaneous USP/NF, European Pharmacopoeia, and Japanese Pharmacopoeia requirements and forms the volume backbone of the market, with Chinese and Indian producers dominating supply. Super Refined grades — characterised by significantly reduced peroxide values, tighter endotoxin limits, and controlled fatty acid profiles — command a meaningful price premium and are increasingly specified for parenteral, ophthalmic, and vaccine applications. At the apex sits Ultrapure grade, produced by fewer than six credentialed manufacturers globally, targeting the most demanding biopharma applications where sub-ppb peroxide levels and ultra-low endotoxin are non-negotiable.
Growth through 2037 is driven principally by the biologics and biosimilar pipeline, the rapid expansion of LNP-based nucleic acid therapeutics, and the broader premiumisation trend as formulators migrate from Multicompendial to higher-purity grades. Countervailing pressures include feedstock price volatility, increasing regulatory scrutiny of polysorbate degradation products — particularly host cell lipase-mediated hydrolysis in bioreactor-manufactured biologics — and nascent substitution interest from polyglyceryl esters and poloxamers in non-parenteral applications. Supply chain concentration at the Ultrapure tier represents a structural risk that biopharma procurement teams are increasingly addressing through dual-source qualification and long-term contractual arrangements.
The Global Polysorbate Market 2027–2037 provides a definitive commercial intelligence resource for organisations operating in or evaluating the global polysorbate market across the ten-year period to 2037. Produced through a combination of primary stakeholder interviews, trade data analysis, pharmacopoeial and regulatory documentation review, and proprietary bottom-up market modelling, it delivers granular revenue and volume forecasts segmented by product type, quality grade, source, physical form, end-use sector, and geography — with all forecasts presented at both 2025 and 2037 endpoints alongside full CAGR analysis.
The report is structured to serve a broad professional readership including polysorbate manufacturers, pharmaceutical formulators and procurement teams, specialty chemical distributors, biopharma CDMOs, regulatory affairs functions, and financial analysts and investors assessing the specialty excipients space. Its most distinctive feature is the three-tier grade framework — Multicompendial, Super Refined, and Ultrapure — applied consistently across market sizing, competitive positioning, pricing analysis, regulatory commentary, and all 19 company profiles, reflecting the commercially critical reality that these grades serve fundamentally different customers, command very different price points, and are supplied by an increasingly divergent set of manufacturers.
A dedicated chapter on the biopharmaceutical polysorbate market — the report's most extensive section — addresses the full spectrum of injectable modalities driving Ultrapure and Super Refined demand growth: monoclonal antibodies, biosimilars, mRNA lipid nanoparticle platforms, gene therapy vectors, oncology injectables, and ophthalmic biologics. This chapter includes detailed treatment of polysorbate degradation risk management, regulatory qualification expectations under ICH Q8 and Q9, DMF and CEP filing status by supplier, and supply security assessment at the Ultrapure tier where fewer than six credentialed manufacturers serve the global market. Regional analysis covers seven geographies with country-level depth in the highest-value markets. The competitive chapter profiles 18 manufacturers in alphabetical order, each assessed against grade breadth, manufacturing footprint, regulatory certifications, strategic direction, and a structured SWOT analysis.
Report Contents include:
Table of Contents
1 EXECUTIVE SUMMARY 16
1.1 Global polysorbate market at a glance (2025–2037) 16
1.2 Key market findings and headline forecast 19
1.3 Critical trends shaping the decade: biologics boom, mRNA platforms, grade premiumisation, clean-label demand 19
1.4 Strategic implications for manufacturers, formulators, and investors 20
2 POLYSORBATE CHEMISTRY, MANUFACTURING & PROPERTIES 22
2.1 Introduction to polysorbates: definition, nomenclature, and history 22
2.2 Chemical structure and composition 23
2.2.1 Sorbitol dehydration: sorbitan and isosorbide backbone formation 24
2.2.2 Fatty acid esterification and polyoxyethylene (POE) chains 26
2.2.3 Compositional heterogeneity: the 27,000+ component reality of PS20 27
2.2.4 HLB values and their implications for formulation performance 29
2.3 Commercial grades overview: Polysorbate 20, 40, 60, 80, and specialty variants 29
2.3.1 Polysorbate 20 (Tween 20 / PS20): laurate-dominant profile 29
2.3.2 Polysorbate 40 (PS40): palmitate-based properties 30
2.3.3 Polysorbate 60 (PS60): stearate-based properties 31
2.3.4 Polysorbate 80 (PS80): oleate-dominant profile and biopharmaceutical dominance 32
2.4 Grade taxonomy: Multicompendial, Super Refined, and Ultrapure 32
2.4.1 Multicompendial grade: specification convergence across USP/NF, Ph. Eur., and JP 33
2.4.2 Super Refined grade: advanced purification, ultra-low peroxides, and endotoxin control 34
2.4.3 Ultrapure grade: single-source material, sub-ppb peroxide, and biopharma-specific CoA 34
2.4.4 Comparison of grade-defining parameters: peroxide value, endotoxin, fatty acid profile, water content 35
2.4.5 Branded grade equivalences: Croda Super Refined, Clariant VitiPure Superior, NOF HX2, SEPPIC Montanox PPI/LPI 36
2.5 Manufacturing process overview 37
2.5.1 Raw materials: sorbitol, ethylene oxide, and fatty acid sourcing 37
2.5.2 Oxyethylation and esterification process steps 38
2.5.3 Purification pathways diverge by grade: standard vs Super Refined vs Ultrapure 40
2.5.4 Nitrogen-purged packaging and peroxide ingress prevention 40
2.5.5 Batch-to-batch variability and GMP quality control challenges 41
2.6 Degradation pathways and stability 42
2.6.1 Oxidative degradation: peroxide formation and monitoring 43
2.6.2 Enzymatic hydrolysis in biopharmaceutical formulations 44
2.6.3 Acidic and alkaline hydrolysis mechanisms 45
2.6.4 Impact of ester species distribution on protein stabilisation 45
2.7 Analytical characterisation methods 46
2.7.1 UPLC-MS: marker-based quantification and composition profiling 46
2.7.2 CAD, ELSD, and mass detection for PS content determination 48
2.7.3 Stochastic modelling: binomial distribution of esterification and OE units 49
2.7.4 Hydroxyl number, saponification value, and peroxide value testing 50
2.7.5 Endotoxin (LAL) and bioburden testing — grade-differentiated requirements 52
3 MARKET OVERVIEW AND MACROECONOMIC CONTEXT 53
3.1 Global specialty chemicals and pharmaceutical excipients industry landscape 53
3.2 Macroeconomic factors influencing polysorbate demand 54
3.2.1 Global biologics, biosimilar, and advanced therapy pipeline growth 54
3.2.2 Processed food and convenience food consumption trends 55
3.2.3 Personal care market expansion and premiumisation 55
3.2.4 Oleochemical and ethylene oxide feedstock price dynamics 56
3.3 Supply chain analysis 57
3.3.1 Raw material suppliers: sorbitol, fatty acid, and ethylene oxide producers 57
3.3.2 Polysorbate manufacturers and toll processors by grade tier 58
3.3.3 Contract manufacturers and CDMOs supplying biopharma-grade polysorbate 59
3.3.4 Distributors, formulators, and end users 60
3.3.5 Supply chain risk and resilience post-2020 61
3.4 Pricing analysis by grade, purity, and geography 61
3.4.1 Multicompendial grade pricing: benchmarks and regional variance 62
3.4.2 Super Refined grade: premium over Multicompendial and cost-benefit for formulators 62
3.4.3 Ultrapure grade: pricing dynamics, supply concentration, and biopharma willingness-to-pay 63
3.4.4 Asia-Pacific price benchmarks vs North America and Europe across all grades 65
3.4.5 Outlook for pricing 2026–2037 65
4 GLOBAL MARKET SIZE, FORECAST & SEGMENTATION 67
4.1 Global polysorbate market value and volume, 2020–2025 (historical) 67
4.2 Global polysorbate market forecast, 2026–2037 68
4.2.1 Revenue forecast (USD million) with CAGR analysis 68
4.2.2 Volume forecast (kilotons) and average selling price evolution 70
4.2.3 Absolute dollar growth and incremental opportunity analysis 72
4.3 Segmentation by product type 73
4.3.1 Market by product type 73
4.3.1.1 Polysorbate 20 — market size, share, and forecast 73
4.3.1.2 Polysorbate 40 — market size, share, and forecast 74
4.3.1.3 Polysorbate 60 — market size, share, and forecast 75
4.3.1.4 Polysorbate 80 — market size, share, and forecast 76
4.3.1.5 Other grades and custom polysorbate blends 77
4.4 Segmentation by grade — Multicompendial, Super Refined & Ultrapure 78
4.4.1 Market by quality grade 78
4.4.1.1 Multicompendial grade — market size, value share, and 2026–2037 forecast 79
4.4.1.2 Super Refined grade — market size, value share, and 2026–2037 forecast 82
4.4.1.3 Ultrapure grade — market size, value share, and 2026–2037 forecast 86
4.4.1.4 Grade migration trends: formulator shift from Multicompendial to Super Refined and Ultrapure 93
4.4.1.5 Forecast: grade share evolution 2026–2037 — Ultrapure CAGR vs overall market CAGR 94
4.5 Segmentation by source 96
4.5.1 Market by source 96
4.5.1.1 Synthetic source (dominant ~60% share) 97
4.5.1.2 Plant-derived / vegetable-oil-based (including RSPO-certified) 98
4.5.1.3 Animal-derived 99
4.5.2 Market by physical form (liquid, paste, powder) 100
4.5.3 Market by end-use sector (pharma, food, cosmetics, industrial) 100
5 POLYSORBATE END-USE MARKETS 102
5.1 Biopharmaceuticals 102
5.1.1 Market sizing and structure 102
5.1.1.1 Biopharma polysorbate market — size, value, and share of total market 102
5.1.2 Polysorbate in biological drug formulation 108
5.1.2.1 Role and function of polysorbate in biopharmaceutical formulations 108
5.1.2.2 Mechanism of action: surfactant stabilisation of protein therapeutics 108
5.1.3 Biologics and biosimilars 114
5.1.3.1 Monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) 114
5.1.3.2 Biosimilars — a structural demand accelerator 118
5.1.4 Vaccines and mRNA platforms 124
5.1.4.1 Vaccine formulations 124
5.1.5 Advanced drug delivery and emerging modalities 131
5.1.5.1 Lipid nanoparticles (LNPs) and nucleic acid therapeutics 131
5.1.5.2 Gene therapy vectors (AAV, lentiviral) and cell therapy 135
5.1.5.3 Recombinant proteins, enzymes, and hormone therapeutics 137
5.1.6 Oncology injectables 140
5.1.6.1 Oncology injectables — small molecule and biologic 141
5.1.7 Ophthalmic and other sterile formulations 145
5.1.7.1 Ophthalmic biologics and sterile formulations 146
5.1.7.2 Regulatory, quality, and supply considerations 150
5.1.8 Supply security and single-source risk in biopharma polysorbate procurement 159
5.2 Food and beverage 163
5.2.1 Ice cream and frozen desserts: anti-melting and aeration functionality 164
5.2.2 Bakery and confectionery: emulsification and anti-staling 164
5.2.3 Sauces, dressings, and condiments 165
5.2.4 Beverages and flavour emulsification 165
5.2.5 Plant-based and vegan food products: demand implications for emulsifier sourcing 166
5.2.6 Regulatory status: E-number approvals (E432–E436) and clean-label pressure 167
5.3 Cosmetics & Personal Care 168
5.3.1 Skincare: creams, lotions, and liquid crystalline structure formation 169
5.3.2 Haircare: shampoos, conditioners, and scalp treatments 170
5.3.3 Fragrance solubilisation in water-based formulations 171
5.3.4 Baby care and sensitive-skin applications 172
5.3.5 Natural and bio-based alternatives: competitive threat assessment 173
5.4 Agrochemicals: dispersants and wetting agents 174
5.5 Industrial and institutional cleaning 175
5.6 Oil and gas applications 176
5.7 Nutraceuticals and dietary supplements 177
6 REGIONAL MARKET ANALYSIS 179
6.1 Regional market overview and production geography 179
6.2 Asia-Pacific — dominant region by volume 180
6.2.1 China 181
6.2.2 India 182
6.2.3 Japan 183
6.2.4 South Korea 183
6.2.5 Southeast Asia 184
6.3 North America 185
6.4 Canada and Mexico 186
6.5 Europe 187
6.6 Latin America 188
6.7 Middle East & Africa 189
7 REGULATORY & QUALITY FRAMEWORK 191
7.1 Pharmaceutical excipient regulatory landscape 191
7.1.1 United States Pharmacopeia (USP) and National Formulary (NF) monographs 191
7.1.2 European Pharmacopoeia (Ph. Eur.) and EDQM requirements 191
7.1.3 Japanese Pharmacopoeia (JP): requirements and NOF HX2 compliance 192
7.1.4 Multicompendial certification: simultaneous USP/Ph. Eur./JP compliance 193
7.1.5 FDA Inactive Ingredient Database (IID) and parenteral-use approvals 194
7.1.6 ICH Q8/Q9/Q10 guidelines and excipient quality management 195
7.1.7 IPEC-GMP and EXCiPACT certification requirements 196
7.1.8 Drug Master File (DMF) and CEP/COS filing — supplier-specific analysis 197
7.2 Grade-specific regulatory expectations 198
7.2.1 Multicompendial grade: pharmacopoeial compliance as minimum bar 199
7.2.2 Super Refined grade: additional industry standards and customer-specified CoA parameters 200
7.2.3 Ultrapure grade: BLA/MAA expectations, endotoxin limits, and elemental impurity control (ICH Q3D) 200
7.3 Food additive regulations 201
7.3.1 EU E-number framework (E432–E436) and EFSA safety assessments 202
7.3.2 US FDA GRAS status and acceptable daily intake (ADI) limits 202
7.3.3 Codex Alimentarius and Asia-Pacific food standards 203
7.4 Cosmetic ingredient safety and labelling requirements 204
7.5 Emerging regulatory pressure: impurity profiling and peroxide value limits 205
7.6 Regulatory impact on market entry and supplier qualification 205
8 MARKET TRENDS, DRIVERS, RESTRAINTS & OPPORTUNITIES 207
8.1 Key growth drivers 207
8.1.1 Biologics and biosimilar market expansion (18+ FDA biosimilar approvals in 2024) 208
8.1.2 mRNA vaccine platform diversification beyond COVID-19 209
8.1.3 LNP and advanced drug delivery system growth — Ultrapure grade catalyst 209
8.1.4 Processed food demand and global population growth 210
8.1.5 Rising healthcare infrastructure investment in emerging markets 211
8.1.6 Grade premiumisation: formulator upgrade from Multicompendial to Super Refined/Ultrapure 211
8.2 Market restraints and challenges 212
8.2.1 Regulatory scrutiny on excipient degradation and impurity profiles 212
8.2.2 Oleochemical and ethylene oxide feedstock volatility 213
8.2.3 Formulation substitution: polysorbate alternatives (polyglyceryl esters, poloxamers) 214
8.2.4 Clean-label and allergen-free consumer pressure in food and cosmetics 215
8.2.5 Specialty chemical sector headwinds and pricing power constraints 216
8.3 Emerging opportunities 216
8.3.1 Bio-based and RSPO-certified polysorbates for sustainability-driven markets 216
8.3.2 Ultrapure-grade capacity expansion for next-generation parenteral applications 217
8.3.3 Digital batch traceability and real-time peroxide monitoring technologies 218
8.3.4 Oncology drug partnerships and specialised long-term supply agreements 219
8.3.5 Veterinary biologics and animal health applications 220
8.4 Technology and innovation trends 221
8.4.1 Advanced UPLC-MS composition profiling and stochastic modelling 222
8.4.2 Process optimisation for ultra-low peroxide: continuous manufacturing approaches 222
8.4.3 Fatty acid source authentication: single-origin supply for Ultrapure grade consistency 223
9 COMPANY PROFILES 225 (18 company profiles)
10 STRATEGIC OUTLOOK & FUTURE SCENARIOS 242
10.1 Scenario planning: base, optimistic, and conservative trajectories to 2036 242
10.2 Grade-level scenarios: Ultrapure share of total market under each trajectory 243
10.3 Investment opportunity map by grade, application, and region 244
10.4 Polysorbate alternatives: substitution risk assessment to 2036 245
11 APPENDICES 248
11.1 Global polysorbate trade flow data and import/export statistics 248
11.2 Polysorbate production capacity database by plant, grade tier, and region 249
11.3 Pharmacopoeia monograph comparison: USP vs Ph. Eur. vs JP — all grades 251
11.4 Grade parameter comparison table: Multicompendial, Super Refined, Ultrapure 252
11.5 Raw material price index: sorbitol, ethylene oxide, lauric acid, oleic acid (2020–2026) 253
11.6 Selected drug formulations containing polysorbates (FDA IID-derived) 254
11.7 Branded polysorbate grade cross-reference: manufacturer / brand name / grade tier 256
11.8 Glossary of technical terms 258
11.9 Research Methodology 259
12 REFERENCES 261
List of Tables/Graphs
List of Tables
Table 1. Global polysorbate market revenue, 2020–2037 (USD million) 17
Table 2. Global polysorbate market — key statistics at a glance 19
Table 3. Summary competitive landscape — 19 profiled companies by tier and grade focus 21
Table 4. Major fatty acid ester species in commercial PS20 by relative abundance (%) 28
Table 5. HLB values, critical micelle concentrations, and solubilisation characteristics across PS20, PS40, PS60, PS80 29
Table 6. Grade parameter comparison — Multicompendial vs Super Refined vs Ultrapure: peroxide value limits, endotoxin thresholds, water content, fatty acid profile control, and packaging requirements 35
Table 7. Branded polysorbate product cross-reference — manufacturer, brand name, grade tier, pharmacopoeial status, and primary application 36
Table 8. Key raw material specifications and quality implications by grade tier 38
Table 9. Sources of batch-to-batch variability — raw material, process, and analytical factors 41
Table 10. Degradation pathway comparison — mechanism, rate drivers, detection methods, and formulation risk 46
Table 11. Analytical method comparison — UPLC-MS, CAD, ELSD, NMR: sensitivity, selectivity, and regulatory acceptance 48
Table 12. Compendial test methods for polysorbate quality characterisation — USP vs Ph. Eur. vs JP 51
Table 13. Polysorbate manufacturers by grade capability — Multicompendial, Super Refined, Ultrapure production footprint 58
Table 14. Supply chain risk register — raw material, manufacturing, logistics, and geopolitical risks by grade tier 61
Table 15. Regional pricing benchmarks — Multicompendial, Super Refined, and Ultrapure PS80 by geography 64
Table 16. Global polysorbate market historical data — revenue, volume, and ASP, 2020–2025 68
Table 17. Global polysorbate market forecast — revenue, volume, ASP, and CAGR by segment, 2026–2037 72
Table 18. PS20 market by application — pharma, food, cosmetics, industrial: value and share, 2025 and 2037 74
Table 19. PS80 market by application — biopharma, food, cosmetics, industrial: value and share, 2025 and 2037 77
Table 20. Market size and share by product type — PS20, PS40, PS60, PS80, other: 2025 and 2037 77
Table 21. Multicompendial grade — leading suppliers, estimated market share, and production geography 81
Table 22. Super Refined grade — leading suppliers, key branded products, and grade-specific specifications 85
Table 23. Ultrapure grade — credentialed manufacturers, key branded products, and indicative price premiums 92
Table 24. Grade segmentation forecast — revenue, volume, value share, and CAGR: Multicompendial, Super Refined, Ultrapure, 2026–2037 94
Table 25. Market by source — value, volume, and growth outlook, 2026–2037 100
Table 26. Market by end-use sector — value, volume, share, and CAGR, 2026–2037 101
Table 27. Biopharma polysorbate market — by modality: mAbs, biosimilars, vaccines, LNPs, gene therapy, oncology injectables: value and CAGR, 2026–2037 105
Table 28. PS20 vs PS80 — formulation selection criteria: stability profile, degradation susceptibility, regulatory precedent, and application suitability 111
Table 29. Polysorbate concentrations in selected approved biologics (mAbs, vaccines, recombinant proteins) — indicative ranges 112
Table 30. Selected approved mAb formulations containing PS80 or PS20 — drug, indication, and polysorbate concentration 115
Table 31. Biosimilar polysorbate grade requirements — reference product analysis and sourcing implications 121
Table 32. Polysorbate grade requirements by vaccine platform — conventional, adjuvanted, mRNA, and viral vector 128
Table 33. Biopharma modality matrix — polysorbate type, grade requirement, and demand trajectory to 2036 139
Table 34. Key oncology injectable formulations using polysorbate — drug, indication, grade requirement, and annual volume estimate 144
Table 35. DMF and CEP/COS status — polysorbate suppliers with active US FDA DMF and EDQM filings 153
Table 36. Polysorbate degradation monitoring — assay types, sensitivity limits, and stage of application in biologics manufacture 156
Table 37. Biopharma polysorbate supply security assessment — grade tier, supplier count, dual-source feasibility, and lead time 162
Table 38. Food & beverage polysorbate market by sub-segment — value, share, and CAGR, 2026–2037 164
Table 39. Cosmetics & personal care polysorbate market by sub-segment — value, share, and CAGR, 2026–2037 169
Table 40. Polysorbate alternatives in cosmetics — polyglyceryl esters, sucrose esters, Quillaja saponins: functional comparison and market share 173
Table 41. Industrial and other application segments — market size, polysorbate type used, and growth outlook 178
Table 42. Regional polysorbate market forecast — revenue, volume, and CAGR by region, 2026–2037 180
Table 43. China polysorbate production capacity estimates by manufacturer and grade tier 181
Table 44. Middle East & Africa polysorbate market — country-level sizing, key end markets, and growth drivers 189
Table 45. Pharmacopoeia monograph comparison — PS20 and PS80: USP/NF vs Ph. Eur. vs JP test parameters and acceptance criteria 193
Table 46. Regulatory certification landscape — 19 profiled manufacturers by pharmacopoeial compliance, DMF status, and quality certification 197
Table 47. Grade-specific regulatory framework — Multicompendial, Super Refined, Ultrapure: applicable standards, filing requirements, and inspection expectations 198
Table 48. Food additive regulatory status — polysorbate 20, 60, 80 by jurisdiction: EU, USA, Codex, China, Japan 203
Table 49. Cosmetic ingredient regulatory summary — INCI name, EU Cosmetics Regulation status, and key labelling requirements 204
Table 50. Polysorbate alternative surfactants — technical performance comparison, regulatory status, and substitution risk by application 214
Table 51. Opportunity assessment matrix — emerging market segments, grade requirements, addressable value, and timeline to materialisation 220
Table 52. Scenario assumptions — key drivers, grade mix, and regional growth rates under base, optimistic, and conservative cases 243
Table 53. Substitution risk by application — probability and impact of polysorbate displacement by alternative surfactants, 2026–2037 245
Table 54. Global polysorbate import/export volumes and values by country, 2022–2025 (HS code 2915/3402) 248
Table 55. Polysorbate production capacity by manufacturer, site, and grade tier — estimated kiloton/year 249
Table 56. Full monograph parameter comparison: PS20 and PS80 — USP/NF, Ph. Eur., JP — test methods, limits, and equivalences 251
Table 57. Definitive grade parameter table — peroxide value, acid value, water content, residual solvents, endotoxin, elemental impurities, fatty acid profile: all three grade tiers 252
Table 58. Selected FDA-approved parenteral drug products containing PS20 or PS80 — drug name, route, concentration, and grade inference 254
Table 59. Complete branded product cross-reference —all commercial polysorbate products, grade tier classification, and pharmacopoeial status 256
List of Figures
Figure 1. Market value share by grade tier, 2025 vs 2036 — Multicompendial, Super Refined, Ultrapure 17
Figure 2. Generalised chemical structure of polysorbate 80 showing sorbitan backbone, oleate ester, and POE chains 23
Figure 3. Schematic comparison of PS20, PS40, PS60, and PS80 structural differences 24
Figure 4. Sorbitol dehydration reaction pathway — sorbitan and isosorbide formation 25
Figure 5. Stochastic model of PS20 molecular species distribution — binomial probability across esterification and OE unit combinations 27
Figure 6. Grade taxonomy pyramid — Multicompendial base, Super Refined mid, Ultrapure apex — with indicative market size and price premium 36
Figure 7. Polysorbate supply chain — raw materials to finished pharmaceutical excipient 38
Figure 8. Polysorbate manufacturing process flow — oxyethylation, esterification, purification, and packaging by grade tier 39
Figure 9. Oxidative degradation pathway — primary and secondary peroxide formation from POE ether cleavage 43
Figure 10. Enzymatic hydrolysis mechanism — host cell lipase (HCLP)-mediated cleavage of fatty acid esters in PS80 44
Figure 11. Representative UPLC-MS chromatogram of commercial PS20 — major species identification and marker compound annotation 47
Figure 12. Polysorbate market positioning within the global specialty chemicals and pharma excipients value chain 53
Figure 13. Oleic acid, lauric acid, sorbitol, and ethylene oxide price indices, 2018–2025 57
Figure 14. Global polysorbate supply chain map — raw materials, manufacturers, distributors, and end users 57
Figure 15. Polysorbate price premium structure — indicative USD/kg ranges by grade tier, 2025 63
Figure 16. Polysorbate average selling price forecast by grade tier, 2026–2037 66
Figure 17. Global polysorbate market revenue (USD million) and volume (kilotons), 2020–2025 67
Figure 18. Global polysorbate market revenue forecast, 2026–2037 (USD million) 69
Figure 19. Global polysorbate market volume forecast (kilotons) and ASP evolution, 2026–2037 71
Figure 20. Polysorbate 20 market revenue and volume, 2020–2037 73
Figure 21. Polysorbate 40 market revenue and volume, 2020–2037 74
Figure 22. Polysorbate 60 market revenue and volume, 2020–2037 75
Figure 23. Polysorbate 80 market revenue and volume, 2020–2037 76
Figure 24. Multicompendial grade market revenue and volume, 2020–2037 80
Figure 25. Super Refined grade market revenue and volume, 2020–2037 84
Figure 26. Ultrapure grade market revenue and volume, 2020–2037 90
Figure 27. Grade share of total polysorbate market by value, 2020–2037 — Multicompendial, Super Refined, Ultrapure 93
Figure 28. Market share by source — synthetic, plant-derived, animal-derived, 2025 and 2037 99
Figure 29. Market share by physical form, 2025 100
Figure 30. Market revenue by end-use sector, 2025 and 2037 100
Figure 31. Biopharma polysorbate market revenue and volume, 2020–2025 103
Figure 32. Biopharma polysorbate market revenue forecast, 2026–2037 (USD million) 104
Figure 33. Biopharma polysorbate consumption by grade tier — Multicompendial, Super Refined, Ultrapure, 2025 and 2037 106
Figure 34. Polysorbate mechanism — micelle formation, interface adsorption, and protein shielding in injectable biologics 108
Figure 35. PS80 vs PS20 usage frequency in approved mAb drug products 115
Figure 36. Global biosimilar approvals by year, 2015–2025, and pipeline count to 2030 119
Figure 37. Polysorbate role in mRNA-LNP vaccine architecture — PEGylated lipid vs polysorbate surface stabilisation 126
Figure 38. Polysorbate demand from vaccine formulation by platform, 2026–2037 130
Figure 39. LNP structural components and polysorbate positioning within the formulation architecture 131
Figure 40. Polysorbate demand from LNP-based nucleic acid therapeutics, 2026–2037 134
Figure 41. Sterile biopharma application segments by polysorbate grade requirement — parenteral, ophthalmic, and inhaled routes 149
Figure 42. Polysorbate degradation risk management framework — detection, mitigation, and grade selection decision tree 155
Figure 43.Food & beverage polysorbate market revenue, 2020–2037 163
Figure 44. Plant-based food market growth and polysorbate emulsifier demand outlook, 2026–2037 166
Figure 45. Cosmetics & personal care polysorbate market revenue, 2020–2037 168
Figure 46. Agrochemical polysorbate market revenue, 2020–2037 174
Figure 47. Global polysorbate market revenue by region, 2025 and 2037 179
Figure 48. Global polysorbate production geography — manufacturing capacity concentration by country 179
Figure 49. Asia-Pacific polysorbate market revenue by sub-region, 2025 and 2037 180
Figure 50. India polysorbate market revenue and forecast, 2020–2037 182
Figure 51. North America polysorbate market revenue by country, 2025 and 2037 185
Figure 52. Europe polysorbate market revenue by country, 2025 and 2037 187
Figure 53. Latin America polysorbate market revenue, 2020–2037 188
Figure 54. Regulatory compliance pathway — new market entrant qualification timeline by grade tier 206
Figure 55. Market drivers and restraints — impact-probability matrix for the global polysorbate market 2026–2037 207
Figure 56. Global biologics and biosimilar market growth, 2020–2037 — polysorbate demand correlation 208
Figure 57. Innovation landscape — polysorbate analytical and manufacturing technology developments, 2022–2026 224
Figure 58. Three-scenario polysorbate market revenue trajectories, 2026–2037 242
Figure 59. Ultrapure grade revenue share of total polysorbate market under three scenarios, 2026–2037 243
Figure 60. Investment opportunity heatmap — grade tier × application × region: growth rate vs market size 244
Figure 61. Raw material price index — sorbitol, ethylene oxide, lauric acid, and oleic acid, 2020–2026 254
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（ケミカル）の最新刊レポート
Future Markets, inc.社の ケミカル分野 での最新刊レポートよくあるご質問Future Markets, inc.社はどのような調査会社ですか?Future Markets, inc.は先端技術に焦点をあてたスウェーデンの調査会社です。 2009年設立のFMi社は先端素材、バイオ由来の素材、ナノマテリアルの市場をトラッキングし、企業や学... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
.png)
